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Abstract
Background: Large multinodular goiter (MNG) in elderly people is a common finding which can
require intervention. The long-term effect of radioiodine therapy on thyroid volume (TV) and
function after recombinant human (rh) TSH pre-treatment was evaluated.
Methods: After baseline evaluation, 40 subjects over 60 years old with a large MNG were treated
with 131I up to the activity of 600 MBq. Nineteen patients were pretreated with rhTSH (0.1 mg on
2 consecutive days; group 1) while 21 subjects underwent treatment without rhTSH pretreatment
(group 2). TV was monitored every 6–12 months by ultrasonography. The median follow-up period
was 36 months.
Results: At the baseline, the groups matched in terms of TV, 24-h radioiodine uptake (RAIU),
urinary iodine and neck complaints. The number of subjects pretreated with anti-thyroid drugs was
significantly (P = 0.01) greater in group 2 than in group 1; TSH was more suppressed (P = 0.003)
and f-T3 was more elevated (P = 0.005) in group 2 than in group 1 patients. RhTSH increased 24-
h RAIU in group 1 up to the baseline level observed in group 2. The 131I activity administered was
similar in both groups. Adverse events were slight and similar in both groups. A permanent post-
radioiodine toxic condition was reported only in 2 patients in group 2. After radioiodine therapy,
hypothyroidism was observed in significantly more group 1 patients than group 2 patients (P =
0.002). While TV was reduced in both groups, the percentage TV reduction recorded at the last
examination was significantly higher (P = 0.03) in group 1 than in group 2. MNG-related complaints
were significantly reduced in both group 1 (P = 0.0001 vs baseline) and group 2 (P = 0.001) patients.
Conclusion: Low radioiodine activities after pretreatment with low-dosage rhTSH are able to
reduce TV and improve MNG-related symptoms in elderly subjects.
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Background
Italy is an area of moderate iodine deficiency, where goiter
is rather common. Goiter due to iodine deficiency
progresses from a diffuse enlargement of the thyroid in
young adults to a multinodular structure with advancing
age [1]. Patients with large multinodular goiter (MNG)
frequently complain of signs and symptoms that range
from a slight sense of constriction to more severe com-
pressive disorders and impaired respiration [1]. While the
functional activity of MNG is variable, in elderly subjects
TSH sometimes declines as a consequence of autonomous
hormonal activity of the nodules, with clinical features
ranging from euthyroidism to sub-clinical or overt hyper-
thyroidism. In these patients, surgery is the standard pro-
cedure but it may be contraindicated because of cardiac,
pulmonary, or other chronic disorders. When surgery is
not practicable or is refused by the patient, radioiodine
(RAI) therapy may be used to reduce thyroid volume (TV)
in enlarged MNG [2-5]; however, the rather low RAI
uptake (RAIU) and the need for intense RAI activity can
make this therapeutic procedure less effective.
Recombinant human TSH (rhTSH) is now used in the
diagnosis and therapy of differentiated thyroid cancer,
and may be of value in some other conditions [6,7]. One
instance is the use of rhTSH to increase RAIU in patients
with benign MNG, as recently reported in a review by Fast
et al. [8]. RhTSH pre-treatment has been shown to
increase thyroid RAIU and to modify the regional distri-
bution of RAI by stimulating RAIU in hypofunctioning
regions within a goiter [9]. Huysmans et al. [10] showed
that a single 0.01–0.03 mg rhTSH dose administered 24-h
before a diagnostic RAI dose was able to double RAIU in
patients with MNG. Subsequently, it was shown that two
0.1 mg doses of rhTSH administered on two successive
days increased the mean RAIU 4.5-fold, a result that
closely parallels the reported effectiveness of a single 0.3
mg dose [11]. Several observational and prospective con-
trolled studies in the last 4 years have demonstrated that
rhTSH combined with RAI treatment can reduce TV by up
to 57% [11-19].
Current literature data seem to indicate that using rhTSH
as an adjuvant to RAI therapy is more effective than using
RAI alone, when the same radioiodine activities are com-
pared. When used for the purpose of calculating the activ-
ity of the RAI dose administered, rhTSH allows lower
amounts of radiation to be used. However, the optimal
rhTSH dose and the minimum effective RAI activity
needed to treat non-toxic MNG remain to be established.
In addition, the absence of a correlation between TV
reduction and post-rhTSH RAIU, area under the curve of
TSH after rhTSH, baseline TV or RAI activity actually
exerted suggests that goiter reduction may depend on
other factors related to rhTSH pre-stimulation, and not
only on the RAI activity applied [7]. Finally, it should be
borne in mind that treatment with rhTSH and RAI has
many undesirable consequences, such as transient hyper-
thyroidism, thyroid pain and acute goiter swelling [6].
In Italy, the maximum RAI activity allowed for therapy in
out-patients is 600 MBq. In a previous study [16] we
assessed 20 elderly patients with large goiters and com-
pared treatment with RAI activities (370–555 MBq, fixed
activity) following two consecutive 0.2 mg doses of rhTSH
with treatment with 131I alone. In comparison with
patients who were treated with 131I alone, those who
received rhTSH had higher transient (lasting 2 weeks) ele-
vation of thyroid hormones, a greater reduction in TV, and
a similar incidence of hypothyroidism about 2 years after
therapy [16].
In the present study, we report the long-term outcome of
a larger group of elderly out-patients with large MNG
treated with weighted 131I activities up to 600 MBq after
pre-treatment with two consecutive 0.1 mg rhTSH doses.
To assess safety, TV reduction and the duration of thyroid
function, the results were compared with those observed
in a group of out-patients matched for age and TV in
whom MNG was conventionally treated with radioiodine
up to 600 MBq.
Methods
Study population and design
We enrolled 49 patients over 60 years of age with a long
history of MNG and symptoms of cervical compression
and esthetic discomfort; in all patients, cytology after fine-
needle aspiration biopsy of suspect nodules was non-
malignant and neck surgery was refused or not feasible,
owing to other severe concomitant diseases. All patients
lived in Liguria or southern Piedmont, Italian regions
where iodine prophylaxis is recommended on account of
mild-to-moderate iodine deficiency [20]. The administra-
tion of anti-inflammatory steroids and beta-blockers was
not contraindicated in any patients, all of whom were on
these drugs when the protocol started.
Twenty-three out-patients (age range 60–84 yr) attending
our Endocrine Unit were selected for RAI therapy after
rhTSH pre-treatment (group 1). While thyroid hormones
were normal in the majority of patients, some patients
displayed a pre-toxic condition (TSH suppressed) on
baseline evaluation. Four of the 23 patients were excluded
from the study on account of high iodine excretion, ele-
vated baseline RAIU, or the need for RAI activity greater
than that allowed for out-patients (n = 2). Table 1 reports
some clinical data on the 19 group 1 patients (age range
60–84 yr) who completed the protocol. Forty-eight and
24-h before the administration of RAI therapy, patients
received 0.1 mg of rhTSH, which was obtained from
freeze-dried vials containing 0.9 mg of the drug (Gen-
zyme, Cambridge, MA, USA), reconstituted with 1 ml ofThyroid Research 2009, 2:6 http://www.thyroidresearchjournal.com/content/2/1/6
Page 3 of 9
(page number not for citation purposes)
sterile water and then diluted to a final concentration of
0.1 mg/ml with normal saline.
Twenty-six out-patients (age range 60–82 yr) attending
our Radiometabolic Therapy Unit were selected for RAI
treatment without rhTSH pre-treatment (group 2). In this
control group, the majority of patients were in a pre-toxic
condition, but in some cases hyperthyroidism was found
on baseline evaluation. Five of these patients were
excluded from the study on account of the need for greater
RAI activity than that allowed for out-patients (n = 1), low
RAIU uptake after methimazole (MMI) discontinuation
(n = 2), and patient refusal (n = 2). Some clinical data on
the 21 group 2 patients (age range 60–82 yr) who com-
pleted the protocol are reported in Table 1.
All patients who were on MMI at the baseline suspended
the drug 3 – 4 weeks before initial thyroid volume (TV)
and 24-h RAIU evaluations and further RAI treatment.
The study was approved by the local ethics committee,
and all patients provided signed informed consent.
Uptake measurements and RAI therapy
RAI therapy was dosed according to TV and RAIU, up to
the maximum allowed dose of 600 MBq for out-patients
in Italy. The individual RAI doses administered were cal-
culated according to the method of Traino et al. [21]. For
each patient, iodine pollution was excluded in advance by
the evaluation of 24-h urinary iodine excretion. Thyroid
131I uptake was determined 24 h after oral administration
of a tracer activity of 0.5 MBq 131I. In group 1 patients,
RAIU evaluation was repeated under rhTSH administra-
tion, just before RAI therapy. From day 0 to day 7 of RAI
therapy, all subjects received a 25 mg oral dose of atenolol
and a 4 mg intramuscular dose of betamethasone daily.
Thyroid size assessment
TV was assessed in all patients by means of ultrasonogra-
phy (US) before 131I treatment, and, in the vast majority,
6, 12 and 24 months after treatment and at irregular inter-
vals thereafter. US was performed on two-dimensional
images by the same operator (MG) and further validated
independently by a second experienced physician by
means of an Esaote AU5 Idea in combination with a 7.5
MHz linear transducer (Esaote, Genoa, Italy). Subjects lay
supine on the examination bed with the neck hyper-
extended. The thyroid lobes were scanned separately.
Assuming that both lobes are geometrically shaped like
rotated ellipsoids, TV was determined by applying the for-
mula width × depth × length × p/6. Width and depth
dimensions were measured in the transverse scan in terms
of the maximum cross-sectional area of the thyroid lobe.
Length was measured in the longitudinal scan of the thy-
roid lobe. When thyroid dimensions were larger than the
field of view of the ultrasound beam, an extended field-of-
view ultrasound or dual-image (split-screen) ultrasound
technique was used. When an isthmus of measurable size
(> 1 ml) was found, its volume was calculated accord-
ingly. All measurements (mm) were obtained by using the
built-in electronic calipers. The sum of the volumes of the
right lobe, left lobe and isthmus was regarded as the total
TV. In patients who had previously undergone thyroid
surgery, TV was calculated on the residual thyroid gland.
Coefficients of variation of repeated US investigations
were less than 20% [16,22].
Table 1: Baseline clinical and laboratory data of outpatients with MNG treated with RAI with (group 1) or without (group 2) rhTSH 
pre-treatment (0.1 mg, on two consecutive days).
Group 1 (n = 19) Group 2 (n = 21) Significance
Age (yr), mean ± SD 71.8 ± 6.7 70.6 ± 6.8 ns
Females/Males 18/1 16/5 ns
BMI (kg/m2) 27.6 ± 1.1 26.4 ± 0.7 ns
Previous surgery (n) 3 3 ns
Previous 131I therapy (n) 2 2 ns
Use of MMI before RAI (n) 5 14 P = 0.01
US TV (ml), mean ± SEM 71.9 ± 8.1 79.5 ± 8.1 ns
(median; range) 65.0; 39 – 171 72; 38–194
TSH (mIU/l), mean ± SEM 0.69 ± 0.11 0.50 ± 0.24 P = 0.003
f-T3 (pmol/l), mean ± SEM 5.1 ± 0.3 5.7 ± 0.1 P = 0.005
f-T4 (pmol/l), mean ± SEM 16.2 ± 0.8 16.6 ± 1.0 ns
Tg (mg/l), mean ± SEM 93.5 ± 21.8 81.5 ± 14.6 ns
Positive thyroid antibodies (n) 4 2 ns
Urinary iodine (mg/l), mean ± SEM 97.2 ± 9.8 79.6 ± 12.9 ns
24-h RAIU (%), mean ± SEM 35.2 ± 3.2 43.4 ± 2.9 ns
131 I activity (MBq), mean± SEM 542.1 ± 18.3 549 ± 13.8 ns
(median; range) 600; 370 – 600 555; 370 – 600Thyroid Research 2009, 2:6 http://www.thyroidresearchjournal.com/content/2/1/6
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Laboratory evaluations
Blood samples for functional thyroid studies were col-
lected at each examination before 131I treatment and dur-
ing the prolonged follow-up period. Serum TSH, serum
free-T3 (f-T3) and free-T4 (f-T4), serum Tg, thyroid perox-
idase antibodies (TPOAb) and Tg antibodies (TgAb) were
evaluated. TSH, f-T3 and f-T4 were measured by means of
ultra-sensitive chemiluminescence immunoassay (Roche
Diagnostics, Mannheim, Germany). Normal ranges are
0.3–4.2 mIU/l for TSH, and 3.9–6.8 pmol/l and 12.0–
22.0 pmol/l for f-T3 and f-T4, respectively. Tg was assayed
by chemiluminescence immunoassay (Roche Diagnos-
tics); the normal Tg value in patients without goiter is <90
mg/l. TPOAb and TgAb were measured by DiaSorin assays
(Saluggia, Italy); concentrations < 50 and <100 mIU/l,
respectively, were regarded as negative. Urinary iodine
concentrations were estimated by means of a calorimetric
analytical method (Ioduria Kit, Cell-tech, Turin, Italy) on
spot urine specimens, and were expressed as mg/l.
Statistical analysis
The primary objective of the study was to evaluate TV after
treatments. Secondary objectives were to evaluate changes
in both subjective symptoms and thyroid function. The
severity of acute (first month after treatment) adverse
events was carefully evaluated. The subjective benefit on
goiter-related symptoms was evaluated by comparing the
patient's assessment of subjective discomfort before treat-
ment with that recorded at the end of the follow-up
period by means of a visual analogical scale (VAS) ranging
from 0 (no complaints) to 10 (subjective maximum
degree of cervical discomfort).
Data were analyzed by means of the Prism 4.0 software
(GraphPad Software, San Diego, CA, USA). All values
quoted are means ± SEM, unless otherwise stated. Signifi-
cance was taken as P < 0.05. To compare continuous or
percentage data, the Kruskal-Wallis analysis of variance
was used, followed by Dunn's Multiple comparison test,
the Mann-Whitney test, the Wilcoxon test and Fisher's
exact test, when appropriate. Correlation analyses
between variables were carried out by the Spearman cor-
relation test.
Results
Baseline clinical and laboratory data
Table 1 reports the baseline clinical and laboratory data of
patients who underwent RAI treatment with (group 1) or
without (group 2) rhTSH (0.1 mg on two consecutive
days) pre-treatment. The majority of patients treated were
females, but no significant difference emerged between
the groups in terms of female/male distribution. The var-
iables age, BMI, previous thyroid surgery, urinary iodine
concentration, and positive thyroid autoimmunity were
similar in both groups. Before RAI therapy, patients with
concomitant hyperthyroidism underwent MMI treatment
in order to prevent overt thyroid hyperfunction; group 2
contained more of these patients than group 1 (14 vs 5)
(P = 0.01). At the baseline, f-T3 levels were slightly but sig-
nificantly higher (P = 0.005) in group 2 than in group 1,
while TSH was lower (P = 0.003). TV and % 24-h RAIU
were similar in both groups. In group 1 patients, RAIU
increased to 45.0 ± 4.1% following rhTSH pre-stimulation
(P = 0.01). The median activity applied was 600 MBq in
group 1 and 555 MBq in group 2 (Table 1). In accordance
with national regulations for out-patients, 131I activity was
restricted to 600 MBq in 11 group 1 patients (58%) and 8
group 2 patients (30%; ns vs group 1), although the opti-
mal activity would have been higher.
Thyroid volume reduction
At the baseline, the median TV was 71.9 ± 8.1 ml in group
1 and 79.5 ± 8.1 ml in group 2 (Table 1). Four patients
from group 2 dropped out during the follow-up period: 3
underwent further RAI therapy (TV reduction 3%, 11%,
and 31% from baseline) after 24 months, and 1 under-
went thyroid surgery (TV reduction 30%) after 42 months.
Figure 1 shows the individual and the mean (± SEM) time-
course trends of TV in each group. Kruskal-Wallis analysis
of variance revealed that TV reduction was greater in
group 1 (P < 0.0001) than in group 2 (P = 0.01). Dunn's
multiple comparison test revealed no further significant
TV reduction from the 6th to the 36th month of follow-up
in either group of patients (Figure 1). The average follow-
up was 33.3 ± 3.2 months (median 36 months; range 12
– 60 months) in group 1 and 36.9 ± 3.4 months (median
36 months; range 12 – 63 months) in group 2 (ns). At the
last evaluation, TV was 29.5 ± 5.2 ml (median 25 ml;
range 1–107 ml) in group 1 (P < 0.0001 vs baseline) and
47.5 ± 8.1 ml (median 40 ml; range 10–172 ml) in group
2 (P < 0.0001 vs baseline) patients. At this evaluation, the
difference in TV between the groups was near to statistical
significance (P = 0.06). Figure 2 reports the mean percent-
age (± SEM) change in TV following RAI in both groups of
subjects. The TV reduction was more evident in group 1
than in group 2 patients. At the last evaluation, the TV
reduction was significantly (P = 0.03) greater in group 1
(60.2 ± 4.4%; median 62%, range 12% – 98%) than in
group 2 (44 ± 5.4%; median 47%, range 0% – 84%). In
both groups, TV reduction was unrelated to age, BMI, ini-
tial TV, thyroid function, baseline RAIU or RAI activity.
Thyroid function and autoimmunity
In the first 4 weeks after RAI treatment, thyroid function
was routinely evaluated. No difference in f-T3 (group 1:
5.9 ± 0.5 pmol/l; group 2: 5.7 ± 0.3 pmol/l), f-T4 (group
1: 19.3 ± 1.9 pmol/l; group 2: 18.6 ± 2.3 pmol/l) or TSH
(group 1: 0.25 ± 0.19 mIU/l; group 2: 0.57 ± 0.19 mIU/l;
P = 0.1) was found 4 weeks after RAI treatment. According
to the results of this evaluation, patients were treated orThyroid Research 2009, 2:6 http://www.thyroidresearchjournal.com/content/2/1/6
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not with MMI. There was no difference between the
groups in the percentage of patients on MMI soon after
RAI (P = 0.1 by Fisher's exact test). MMI was restarted for
3–12 months in 4 out of 5 group 1 patients previously
treated with MMI. In group 2, MMI was restarted in 6
patients previously treated with MMI and in 1 other
patient; 5 patients were treated for 3–12 months and 2 for
24 months. Only in group 1 patients (n = 7) did perma-
nent hypothyroidism develop within the first year after
RAI; in these patients, L-T4 was started. At the last exami-
nation, the percentage of patients on L-T4 was signifi-
cantly higher (P = 0.002) in group 1 than in group 2
(Table 2). Table 2 reports data on thyroid function, thy-
roid autoimmunity and ongoing thyroid treatment at the
last examination in groups 1 and 2. In all patients, thyroid
function was in the normal range at the last examination,
both in those on L-T4 or MMI and in those off thyroid
drugs. Moreover, f-T3 levels were still slightly, but signifi-
cantly (P = 0.001), higher in group 2 than in group 1
(Table 2).
Subjective complaints
No adverse events were reported by 4 group 1 subjects and
6 group 2 subjects in the first 4 weeks after RAI therapy.
The complaints reported by the other subjects in both
groups were generally short-lived. The most frequent com-
plaint in both groups was "neck trouble". Two patients
were hospitalized after RAI: one from group 1 on day 7
owing to hyperkinetic arrhythmia and one from group 2
on day 6 owing to respiratory insufficiency due to con-
comitant chronic obstructive pulmonary disease.
Figure 3 reports mean VAS scores on enrolment and at the
last examination. At the baseline, no difference in VAS
scores was noted between the groups. In both groups,
baseline VAS scores were unrelated to TV. At the last exam-
ination, VAS scores were significantly reduced in both
groups of patients but the reduction from the baseline was
more significant in group 1 (P = 0.0001) than in group 2
(P = 0.001) patients (Figure 3). No change (n = 2) or a
slight reduction (n = 2) in VAS score was noted in the 4
Individual TV observed over 36 months of follow-up in group  1 (upper panel) and group 2 (lower panel) patients Figure 1
Individual TV observed over 36 months of follow-up 
in group 1 (upper panel) and group 2 (lower panel) 
patients. Mean ± SEM data are also shown (closed circles). 
Significances by Dunn's multiple comparison test vs baseline 
are: a P < 0.01, b P < 0.05.

































Change in TV over 36 months of follow-up in group 1  (closed circles) and group 2 (open circles) Figure 2
Change in TV over 36 months of follow-up in group 1 
(closed circles) and group 2 (open circles). TV at the 
various time-points is expressed as a percentage (mean ± 
SEM) of the baseline value. Significances between groups are: 
a P = 0.001, b P = 0.01, c P = 0.03. The number of patients is 
shown in brackets.
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group 2 patients who dropped out of the study 24 months
after RAI in order to undergo further RAI treatment or thy-
roidectomy.
Discussion
While surgery remains the gold standard in the treatment
of MNG, several recent studies have demonstrated that
RAI therapy with adjuvant rhTSH pre-treatment can be an
attractive alternative [11-19]. The prevalence of MNG rises
in the elderly, who also often suffer from comorbities
[23]. Although many patients enrolled in the several
observational, prospective and controlled studies were
more than 60 years old, few studies involving this new
therapeutic protocol have so far focused on elderly sub-
jects [15,16].
In the present study we prospectively evaluated 40 outpa-
tients with a mean age of 71 years. Within the limits of our
protocol (the patients were consecutively recruited with-
out randomization, and rhTSH administration was not
blinded/placebo-controlled) the results obtained docu-
mented a greater reduction in TV when rhTSH treatment
preceded RAI therapy than when similar RAI activities
were applied alone. A significant, effective and permanent
TV reduction is the main outcome of RAI therapy for
MNG in the elderly. In our previous study [16], fixed
doses of RAI (370 to 555 MBq) alleviated symptoms in all
but one patient following rhTSH administration (0.2 mg
on two consecutive days), and yielded a mean 50% reduc-
tion in TV after about 2 years. In the present study, TV
reduction was greater in the rhTSH-treated group 6–12
months after RAI therapy; thereafter, a slow decline in TV
was maintained. On long-term follow-up (median 36
months) evaluation, a 62% reduction was found, which
was 15% greater than after RAI alone. So far, rhTSH-pre-
treated patients have not required any further treatment to
reduce TV, while some patients treated with RAI alone
have required further RAI therapy or surgery.
It should be noted that the sample of patients we enrolled
comprised both patients with euthyroid MNG and
patients with MNG and subclinical hyperthyroidism, as in
other series [11,14,16,18,19]). More patients in group 2
(no rhTSH pretreatment) had subclinical hyperthy-
roidism; consequently, more group 2 patients were
treated with low-dose MMI before RAI. This constitutes a
potential bias of the study. However, in our opinion, the
results of RAI are fairly comparable between the 2 groups,
bearing in mind that baseline RAIU and TV were very sim-
ilar.
It is not easy to compare the data from the various studies,
owing to differences in sample populations and therapeu-
tic protocols (different amounts of rhTSH from 0.03 to
0.45 mg; different RAI doses from 370 to 5550). However,
Cohen et al. [14] reported a 30% reduction in TV after a 6-
month follow-up, which is roughly comparable to that
found in our patients. We observed a 50% reduction in TV
after 12 months, which is similar to that seen in other
studies [11,14,18,19].
It is not clear how long rhTSH and RAI exert their reducing
effect on TV. In a follow-up study lasting up to 12 months,
Paz-Filho et al. [24] reported an average 50% reduction in
TV after RAI (1110 MBq) in patients with an initial TV of
Table 2: Laboratory data and numbers of patients on therapy to normalize thyroid parameters in MNG out-patients treated with RAI 
with (group 1) or without (group 2) rhTSH pre-treatment (0.1 mg, on two consecutive days).
Group 1 Group 2 Significance
TSH (mIU/l) 1.61 ± 0.19 1.36 ± 0.19 ns
f-T3 (pmol/l) 4.0 ± 0.1 4.6 ± 0.1 P = 0.001
f-T4 (pmol/l) 15.3 ± 0.5 14.7 ± 0.6 ns
Tg (mg/l) 168.3 ± 50.4 337.7 ± 268.7 ns
Positive thyroid antibodies (n) 5 3 ns
L-T4 treatment (n) 12 3 P = 0.002
MMI treatment (n) 0 2 ns
Mean (± SEM) scores self-reported by patients by means of  an ad hoc VAS scale administered to all patients at the base- line (closed bars) and at the last examination (open bars) Figure 3
Mean (± SEM) scores self-reported by patients by 
means of an ad hoc VAS scale administered to all 
patients at the baseline (closed bars) and at the last 
examination (open bars).
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100 ml pre-treated with rhTSH (0.1 or 0.2 mg); most
(about 70%) of this reduction occurred in the 1st year after
treatment. On the other hand, Cardia et al. [25] reported
data from a 3-year follow-up of patients involved in a pre-
viously published study [14]. At the last evaluation of
available patients, ongoing TV reduction was observed
from the 1st to the 4th year after RAI therapy; moreover, the
initial difference in TV reduction in favor of rhTSH-pre-
treated patients persisted (on average, 70% with rhTSH
plus RAI vs 60% with RAI alone [25]. The trend in our data
suggests that a similar percentage reduction in TV can be
achieved by using lower RAI activities (up to 600 MBq
instead of up to 5550 MBq). On the whole, we think that
the expected degree of final TV reduction after rhTSH plus
RAI is in any case greater than that observed in long-term
follow-up studies after RAI alone [3-5].
Forecasting TV reduction is an unresolved issue. We did
not find any correlation between TV reduction and age,
BMI, initial TV, thyroid function, baseline RAIU or the RAI
dose administered. Similar results have been reported by
Paz-Filho et al. [19]. According to Bonnema et al. [18], TV
reduction may be related to initial TV if the goiter is very
large, which is the most frequent situation in elderly
patients eligible for rhTSH plus RAI therapy. However,
they found that the reduction in the volume of the goiter
after rhTSH and RAI was unrelated to the thyroid dose
retained, an observation in line with other studies con-
ducted on patients with smaller goiters [17]. Our data,
which were obtained at low RAI activity, suggest that the
effect of rhTSH depends on factors independent of thyroid
irradiation. It is plausible that rhTSH might induce the
reactivation of dormant thyroid tissue, or render thyro-
cytes more vulnerable to ionizing radiation [18]. Indeed,
the existence of such preconditioning by TSH has been
suggested in studies of hyperthyroid patients treated with
RAI [26].
Hypothyroidism and the need for L-T4 treatment might
be seen in our protocol as an unwelcome effect of rhTSH
pre-treatment. During follow-up, we observed hypothy-
roidism in 63% of rhTSH-pre-treated patients, while L-T4
treatment was necessary in only 14% of patients treated
with RAI alone. This difference could be explained by a
difference in functional status between the two groups on
enrolment (more thyroid hyperfunction in the group
treated with RAI alone), while a different autoimmune
response is not proven. Moreover, the efficacy of RAI treat-
ment in MNG is usually hampered by the low and irregu-
lar RAIU [1], and it has been shown that rhTSH increases
RAIU ([9], [13]), thereby enhancing the adsorbed activity
[27].
In subjects (mean age 63 years) with large MNG (59%
toxic MNG) treated with high rhTSH (0.45 mg) and RAI
(up to 5550 MBq) dosages, Silva et al. [14] observed
hypothyroidism in 35% of subjects one year after therapy,
as against only 21% (70% toxic MNG) of subjects treated
with RAI alone. In another study, Cohen et al. [15] inves-
tigated 17 patients (aged >60 years) with a large percent-
age of toxic MNG (70% of cases); six months after very
low rhTSH doses (0.03 mg) administered 24-h before
1100 MBq of RAI, hyperthyroidism was seen to have dis-
appeared in 82% of cases and hypothyroidism in only
18%. In a study by Paz-Filho et al. [19] of 17 subjects
(aged >60 years) with normal (n = 12) or increased (n =
5) thyroid function on enrolment, 53% of subjects dis-
played hypothyroidism 1–2 years after 0.1 rhTSH pre-
treatment and 1100 MBq RAI therapy. More recently, Paz-
Filho et al. [24] reported data on two cohorts of patients
pre-treated (0.2 mg) or not with rhTSH before RAI (1100
MBq); on 2-year follow-up examination, they found a
higher prevalence of hypothyroidism in the pretreated
(73%) than in the non-pretreated group (53%).
Rubio et al. [28] have claimed that TPOAb positivity may
occur after RAI, regardless of rhTSH pretreatment, and
Paz-Filho et al. [19] have suggested that TPOAb positivity
and the presence of smaller goiters may increase the risk
of developing hypothyroidism. Our data do not support
these hypotheses, since only a few new cases of autoanti-
body positivity appeared after RAI. On the whole, the
available data seem to indicate that early hypothyroidism
after rhTSH pretreatment is more frequent than after RAI
alone, irrespective of rhTSH dosages and RAI activities.
However, the possibility cannot be ruled out that the dif-
ference observed is due, at least in part, to differences in
baseline thyroid function between the two groups of
patients.
Elderly patients with large MNG may have underlying car-
diovascular disease, and rhTSH and RAI administration
may engender a risk of cardiac complications, owing to
the increase in thyroid hormones. In a recent report by
Barca et al. [29] on patients aged 42 – 80 years who were
treated with a fixed 1100 MBq activity of RAI after 0.1 mg
of rhTSH, a 3-fold increase in left ventricular diastolic dys-
function was seen in subjects with laboratory evidence of
hyperthyroidism. This [29], as well as other previous stud-
ies [11], indicates that beta-blockers should be routinely
administered to reduce thyrotoxic symptoms when rhTSH
and RAI therapy are administered. In our protocol, at least
one daily 25 mg dose of atenolol was administered by
default; only one patient from the rhTSH and RAI group
suffered a severe, albeit transient, cardiovascular adverse
event, while in the RAI group an increase in pre-existing
dyspnea was sometimes reported. This indicates that, in
selected elderly subjects, the adjuvant administration of
rhTSH does not worsen RAI-induced cardiovascular
adverse events. On the other hand, in our patients theThyroid Research 2009, 2:6 http://www.thyroidresearchjournal.com/content/2/1/6
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simultaneous administration of anti-inflammatory ster-
oids resulted in less symptomatic swelling of thyroid tis-
sue, a condition which has been reported by 10% to 30%
of patients after rhTSH and RAI [18].
On the basis of the present and previous studies, rhTSH
pre-stimulation can improve the goiter reduction
achieved by RAI therapy. Administering small doses of
RAI and rhTSH can limit side-effects without compromis-
ing the goiter-reducing effect, while improving MNG-
related symptoms in elderly subjects. RhTSH-induced 131-
I uptake in less active thyroid areas of the goiter, and per-
haps rhTSH-induced mechanisms other than the increase
in thyroid uptake, could explain the better results
achieved by using rhTSH as an adjunct to RAI therapy.
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